6:26 PM
 | 
Nov 29, 2012
 |  BC Extra  |  Company News

Merck withdraws ridaforolimus MAA

Merck & Co. Inc. (NYSE:MRK) withdrew an MAA in the EU for ridaforolimus as maintenance therapy for patients with soft tissue sarcoma or primary malignant bone tumor. According...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >